GlassScriptPhysician profile
Lara Haun
NPI 1982844338
$2,275.15
in general payments reported to CMS, 2019-2025
30 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $120 · 2021: $441 · 2022: $389 · 2023: $290 · 2024: $185 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.69 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.21 | 2019-2022 | |
| Hologic Sales and Service, LLC | $355.74 | 2021-2025 | Aptima |
| Duchesnay USA Incorporated | $182.93 | 2019 | |
| Mayne Pharma Commercial LLC | $171.43 | 2023-2025 | |
| Pfizer INC. | $159.52 | 2019-2025 | |
| Biotissue Holdings INC. | $150.87 | 2022 | |
| Astellas Pharma US INC | $71.36 | 2021-2023 | Veozah |
| Mylan Pharmaceuticals INC. | $69.26 | 2019-2021 | |
| Avion Pharmaceuticals | $64.52 | 2020-2023 | Balcoltra |
| Evofem Biosciences, INC. | $63.94 | 2021-2023 | Phexxi |
| Exeltis, USA INC. | $62.61 | 2021-2023 | Slynd |
| Millicent US INC | $60.34 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $57.53 | 2021 | |
| Roche Diagnostics Corporation | $56.84 | 2019 | |
| Organon LLC | $51.88 | 2022-2023 | Nexplanon |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $51.34 | 2023-2025 | Accrufer |
| Myovant Sciences INC. | $30.19 | 2021-2022 | |
| Therapeuticsmd, INC. | $29.73 | 2021-2022 | |
| Avanos Medical | $27.52 | 2021 | |
| Merck Sharp & Dohme LLC | $26.50 | 2019-2022 | |
| Acessa Health INC. | $22.31 | 2019 | |
| Radius Health, INC. | $18.49 | 2019 | |
| Coopersurgical, INC. | $17.32 | 2024 | Paragard T 380a |
| Aspira Women'S Health INC | $17.08 | 2019 | |
| Sage Therapeutics, LLC | $15.24 | 2020 | |
| Axsome Therapeutics, INC. | $15.21 | 2023 | Auvelity |
| Davol INC. | $13.66 | 2024 | Arista Ah Flexitip |
| Amag Pharmaceuticals, INC. | $12.99 | 2019 | |
| Minerva Surgical, INC | $12.30 | 2019 | |
| Meditrina | $4.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Haun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.